Abstract: Objective: To evaluate the effectiveness and safety of Naoxintong for treating patients with clopidogrel resistance after percutaneous coronary intervention (PCI). Methods: 108 patients with clopidogrel resistance after PCI were randomly divided into clopidogrel group, Naoxintong group and ticagrelor group with 36 patients in each group. After PCI, the patients in clopidogrel group took 150mg (qd) clopidogrel; the patients in Naoxintong group took 150mg (qd) clopidogrel and 0.8mg Naoxintong capsule (tid); the patients in ticagrelor group took 90mg ticagrelor(bid). The platelet aggregation rate (1 week and 1month after treatment) and adverse reactions of patients in 3 groups were recorded. Results: The platelet aggregation rate of patients in Naoxintong group and ticagrelor group after treatment were all obviously lower than that before treatment (P<0.05); also obviously lower than clopidogrel group after treatment (P<0.05). In addition, the platelet aggregation rate of patients in ticagrelor group 1 month after treatment was obviously lower than Naoxintong group (P<0.05). There was no significant difference in incidence rate of bleeding events between the three groups (P<0.05); But the incidence rate of dyspnea of ticagrelor group (11.11%, 4/36) was obviously higher than clopidogrel group and Naoxintong group (P<0.05). Conclusions: Naoxintong can improve the antiplatelet effects of CR patients after PCI and has less side effects,so it is worthy of clinical expansion.

Key words: Naoxintong, Clopidogrel resistance, Ticagrelor, Platelet aggregation rate

摘要： 目的: 评价经皮冠脉介入治疗（percutaneous coronary intervention,PCI）术后氯吡格雷抵抗患者应用脑心通的有效性和安全性。方法: 在我院接受PCI治疗后发生氯吡格雷抵抗的患者108例,随机分为氯吡格雷组、脑心通组与替格瑞洛组各36例。氯吡格雷组患PCI术后者服用氯吡格雷150mg,qd;脑心通组,在服用氯吡格雷（150mg,qd）的基础上加用脑心通胶囊0.8g,tid;替格瑞洛组患者服用替格瑞洛90mg,bid。观察记录三组患者治疗前后的血小板聚集率和不良反应。结果: 脑心通组、替格瑞洛组治疗后的血小板聚集率明显低于本组治疗前（P<0.05）,亦明显低于氯吡格雷组治疗后（P<0.05）;并且,治疗1个月时,替格瑞洛组的血小板聚集率明显低于脑心通组（P<0.05）。三组患者出血事件发生率比较,差异无统计学差异（P>0.05）;替格瑞洛组（11.11%,4/36）呼吸困难发生率明显高于氯吡格雷组和脑心通组（P<0.05）。结论: 脑心通能改善PCI术后氯吡格雷抵抗患者的抗血小板效果,且副作用较小,值得临床推广。

关键词: 脑心通, 氯吡格雷抵抗, 替格瑞洛, 血小板聚集率